New obesity drug AZD1043 enters first human tests

NCT ID NCT07511205

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This early-stage trial tests a new drug called AZD1043 in 104 healthy adults who are overweight or obese. The goal is to check the drug's safety and how the body processes it. Participants receive either the drug or a placebo by injection. The study includes people of Japanese and Chinese descent to see if there are differences.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD1043
What this could lead to: If successful, this could lead to a new weight-control medication for people with obesity.
What could go wrong: This is an early Phase 1 trial with only 104 healthy volunteers, so safety and effectiveness are not yet proven. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS OBESITY

Contacts and locations

Locations

Research Site
RECRUITING

Glendale, California, 91206, United States
Research Site
NOT_YET_RECRUITING

Brooklyn, Maryland, 21225, United States
Research Site
NOT_YET_RECRUITING

Harrow, HA1 3UJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.